Palvella Therapeutics Inc Logo
US6979471090
A40RA6
PVLA

Palvella Therapeutics Inc

Previsão

O preço-alvo médio dos analistas é € 210,03 (+59,11%). A mediana é € 211,67 (+60,36%).

Comprar
  12
Manter
  0
Vender
  0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

  • Palvella presents QTORIN NDA and focuses on rare skin and vascular diseases

    At the Cantor Health conference Palvella outlined its focused strategy for rare skin diseases and vascular anomalies and confirmed submission of an NDA to the FDA for QTORIN (rapamycin) to treat microcystic lymphatic malformations (microLM). If granted a Priority Review, approval could occur in the first half of 2027; Phase III data showed improvement in 95% of patients. The company estimates at least 30,000 diagnosed US microLM patients and aims for an annual treatment price range of $100,000–$200,000, relies on extensive patent protection through at least 2038, and is pursuing additional programs for cutaneous venous malformations and DSAP. » Mais em de.investing.com


  • Palvella prepares NDA submission for QTORIN Rapamycin and builds sales organization

    Palvella plans to file a rolling NDA for QTORIN Rapamycin for microcystic lymphatic malformations later this year and targets a potential US approval in the first half of 2027. The Phase III trial met its primary endpoint: 95% of patients showed improvement and 86% were rated as markedly/very markedly improved. The company has USD 251 million in cash, is preparing a commercial launch with a 40-person sales team and is targeting a treatment price of USD 100,000–200,000 per patient/year. In parallel, Palvella plans to expand QTORIN into additional indications (cutaneous venous malformations, angiokeratomas, DSAP) and to broaden the pipeline by year-end. » Mais em de.investing.com


  • Palvella advances launch preparations; stock rises despite Q2 loss

    Palvella reported a second-quarter loss of $1.52 per share (expectation -$1.16) and no revenue, but the stock rose 4.2% pre-market. The company has about $251 million in cash following a $230 million financing round and raised its expected 2026 cash burn to $85–95 million to expand sales, patient services and launch activities. Lead program QTORIN Rapamycin remains on track for an NDA submission in the second half of 2026 and potential FDA approval in the first half of 2027; Phase III data showed a 95% improvement in the primary endpoint. Management emphasizes financial flexibility and a focus on approval and commercialization preparations, but notes risks from regulation, execution and higher costs. » Mais em de.investing.com


  • Palvella Therapeutics moves to Nasdaq Global Market after strong share price rise

    Palvella Therapeutics has received approval to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Market; the move takes effect at the start of trading on Wednesday and the ticker symbol PVLA remains unchanged. The stock rose 444% last year and is currently at $125.79, with a market capitalization of about $1.8 billion. Analyst views are mixed: InvestingPro considers the stock overvalued, while Stephens rates Palvella “Overweight” with a $220 price target. The company reported strong financial and operational progress in Q1 2026, a robust cash position and promising clinical results, although stock reactions reflected expectations about future earnings and market conditions. » Mais em de.investing.com


  • Palvella reports $261.9m liquidity and aims for QTORIN market launch in 2027

    Palvella reported strong phase‑3 results for QTORIN (rapamycin) in microcystic lymphatic malformations and plans an NDA filing in H2 2026 targeting a U.S. launch in H1 2027. The company closed Q1 with $261.9m in liquidity after an upsized $230m capital raise and views the funds as sufficient through approval. Palvella cites a U.S. sales potential of over $1bn for the main indication and is advancing multiple pipeline programs (cutaneous venous malformations, angiokeratomas, DSAP) with upcoming phase‑2/3 milestones. Despite the progress, the stock fell about 12% as investors weighed the timing to profitability and the valuation. » Mais em de.investing.com

Dados financeiros

No último trimestre, Palvella Therapeutics Inc registou receitas de € 0 e um ganho líquido de -€ 21,76 mi

(EUR) setembro de 2026
YoY
Receitas 0 -
Ganho bruto 0 -
Ganho líquido -21,76 mi 125,05%
EBITDA -19,27 mi 6.712,85%

Dados fundamentais

Métrica Valor
Capitalização bolsista
€ 1,91 bi
Número de ações
14,62 mi
Máximo/mínimo de 52 semanas
€ 164,18 - € 65,89
Dividendos Não
Beta
-0,17
PER (PE Ratio)
-26,06
PEG (PEG Ratio)
7,33
P/VC (PB Ratio)
10,52
P/V (PS Ratio)
0,00

Perfil da empresa

Nome
Palvella Therapeutics Inc
CEO
Wesley H. Kaupinen
Sede Wayne, pa
EUA
Site
Setor
Cuidados de saúde
Indústria
Biotecnologia
Colaboradores 29

Símbolos de ticker

Bolsa Símbolo
NASDAQ
PVLA
🍪

Parqet  utiliza cookies. Saber mais